Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study

© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

¹Institute of Radiology and Nuclear Medicine Kaiser Passage and PET/CT Centre, Johanniter Hospital, Bonn, Germany;
²Klinikum Westfalen and MVZ Prof. Uhlenbrock and Partner, Dortmund, Germany;
³Marienhospital Stuttgart, Stuttgart, Germany;
⁴Diakovere Henriettenstift, Hannover, Germany;
⁵Klinikum Weiden, Weiden, Germany;
⁶Helios Kliniken Schwerin, Schwerin, Germany;
⁷Department of Nuclear Medicine, Klinikum Frankfurt (Oder) GmbH, Frankfurt, Germany;
⁸Department of Nuclear Medicine, University Hospital RWTH Aachen University, Aachen, Germany, and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands;
⁹Bayer HealthCare Pharmaceuticals, Whippany, New Jersey;
¹⁰Bayer AG, Berlin, Germany; and
¹¹Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

For correspondence or reprints, contact Holger Palmedo (holger.palmedo{at}gmx.de).